NZ751713A - Aminopyrimidines as alk inhibitors - Google Patents
Aminopyrimidines as alk inhibitorsInfo
- Publication number
- NZ751713A NZ751713A NZ751713A NZ75171317A NZ751713A NZ 751713 A NZ751713 A NZ 751713A NZ 751713 A NZ751713 A NZ 751713A NZ 75171317 A NZ75171317 A NZ 75171317A NZ 751713 A NZ751713 A NZ 751713A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- isopropylsulfonyl
- diamine
- pyrimidine
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380818P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/048845 WO2018044767A2 (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ751713A true NZ751713A (en) | 2022-07-01 |
Family
ID=59846649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ751713A NZ751713A (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10709705B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3504203B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7094566B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102530871B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109715620B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017319135B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL264638B (cg-RX-API-DMAC7.html) |
| MX (2) | MX389265B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ751713A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201914030UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018044767A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020024825A1 (en) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for treating cancer by combination of fak/alk/ros1 inhibitor and egfr inhibitor |
| CN111171033B (zh) * | 2018-11-09 | 2021-11-02 | 天津大学 | 一种嘧啶衍生物及其合成方法和应用 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CN110143947B (zh) * | 2019-05-29 | 2021-10-15 | 华东师范大学 | 一种色瑞替尼类似物的制备方法 |
| TWI769470B (zh) * | 2019-06-25 | 2022-07-01 | 大陸商蘇州亞盛藥業有限公司 | 用於治療疾病的fak抑制劑和btk抑制劑的組合 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022063220A1 (en) * | 2020-09-25 | 2022-03-31 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
| US20240316051A1 (en) * | 2021-04-19 | 2024-09-26 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| JP2024544576A (ja) * | 2021-12-09 | 2024-12-03 | オンコビクス・カンパニー・リミテッド | 癌細胞成長への抑制効果を示す新規ヘテロ環置換ピリミジン誘導体及びそれを含む医薬組成物 |
| CN116332919B (zh) * | 2022-03-30 | 2025-08-26 | 苏州亚盛药业有限公司 | 一种alk抑制剂化合物及其中间体的制备方法 |
| AU2024210803A1 (en) | 2023-01-20 | 2025-07-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystal form of alk inhibitor or salt and solvate thereof, preparation method therefor, and use thereof |
| KR20250160958A (ko) * | 2023-03-22 | 2025-11-14 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 약학적 조합 및 이의 응용 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| SI2287156T1 (sl) | 2003-08-15 | 2013-09-30 | Novartis Ag | 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema |
| CN100584832C (zh) * | 2003-09-18 | 2010-01-27 | 诺瓦提斯公司 | 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类 |
| DK2253614T3 (da) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| EP2311807B1 (en) | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| KR101238585B1 (ko) | 2008-04-07 | 2013-02-28 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| AU2011315831B2 (en) | 2010-10-14 | 2015-01-22 | Takeda Pharmaceutical Company Limited | Methods for inhibiting cell proliferation in EGFR-driven cancers |
| MX2013008791A (es) * | 2011-02-02 | 2013-10-07 | Irm Llc | Metodos para usar inhibidores de alk. |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| KR101656382B1 (ko) | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
-
2017
- 2017-08-28 WO PCT/US2017/048845 patent/WO2018044767A2/en not_active Ceased
- 2017-08-28 CN CN201780057518.0A patent/CN109715620B/zh active Active
- 2017-08-28 KR KR1020197007075A patent/KR102530871B1/ko active Active
- 2017-08-28 EP EP17764949.8A patent/EP3504203B1/en active Active
- 2017-08-28 SG SG10201914030UA patent/SG10201914030UA/en unknown
- 2017-08-28 SG SG11201901251SA patent/SG11201901251SA/en unknown
- 2017-08-28 NZ NZ751713A patent/NZ751713A/en unknown
- 2017-08-28 EP EP21212760.9A patent/EP4001273A3/en not_active Withdrawn
- 2017-08-28 CN CN202210533398.XA patent/CN115043821B/zh active Active
- 2017-08-28 US US15/559,445 patent/US10709705B2/en active Active
- 2017-08-28 JP JP2019511664A patent/JP7094566B2/ja active Active
- 2017-08-28 AU AU2017319135A patent/AU2017319135B2/en active Active
- 2017-08-28 MX MX2019002393A patent/MX389265B/es unknown
-
2019
- 2019-02-04 IL IL264638A patent/IL264638B/en unknown
- 2019-02-27 MX MX2022000376A patent/MX2022000376A/es unknown
-
2020
- 2020-06-29 US US16/914,518 patent/US11110090B2/en active Active
-
2021
- 2021-05-14 AU AU2021203098A patent/AU2021203098B2/en active Active
-
2022
- 2022-06-15 JP JP2022096630A patent/JP2022120151A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109715620A (zh) | 2019-05-03 |
| WO2018044767A2 (en) | 2018-03-08 |
| SG11201901251SA (en) | 2019-03-28 |
| AU2021203098A1 (en) | 2021-06-10 |
| IL264638B (en) | 2021-08-31 |
| CN109715620B (zh) | 2022-05-06 |
| US11110090B2 (en) | 2021-09-07 |
| EP4001273A2 (en) | 2022-05-25 |
| CA3033223A1 (en) | 2018-03-08 |
| CN115043821A (zh) | 2022-09-13 |
| US20190175595A1 (en) | 2019-06-13 |
| JP7094566B2 (ja) | 2022-07-04 |
| JP2019528307A (ja) | 2019-10-10 |
| US10709705B2 (en) | 2020-07-14 |
| MX389265B (es) | 2025-03-20 |
| AU2021203098B2 (en) | 2023-05-25 |
| MX2019002393A (es) | 2019-07-08 |
| EP3504203A2 (en) | 2019-07-03 |
| AU2017319135A1 (en) | 2019-04-04 |
| JP2022120151A (ja) | 2022-08-17 |
| AU2017319135B2 (en) | 2021-03-18 |
| MX2022000376A (es) | 2022-02-10 |
| SG10201914030UA (en) | 2020-03-30 |
| CN115043821B (zh) | 2024-08-06 |
| BR112019003897A2 (pt) | 2019-05-21 |
| EP3504203B1 (en) | 2022-09-28 |
| EP4001273A3 (en) | 2022-08-24 |
| US20200330464A1 (en) | 2020-10-22 |
| KR20190039760A (ko) | 2019-04-15 |
| KR102530871B1 (ko) | 2023-05-09 |
| WO2018044767A3 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203098B2 (en) | Aminopyrimidines as ALK inhibitors | |
| US11168082B2 (en) | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | |
| US11944614B2 (en) | Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors | |
| WO2019179482A1 (en) | 5, 6-dihydro-11h-indolo [2, 3-b] quinolin-11-one compounds as alk inhibitors | |
| EP3262045A1 (en) | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors | |
| US10781208B2 (en) | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | |
| CA3033223C (en) | Aminopyrimidines as alk inhibitors | |
| HK40077976A (en) | Aminopyrimidines as alk inhibitors | |
| BR112019003897B1 (pt) | Compostos de aminopirimidinas como inibidores de alk, composição farmacêutica bem como seus usos | |
| HK40012150A (en) | 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors | |
| HK40007649A (en) | Aminopyrimidines as alk inhibitors | |
| HK40007649B (en) | Aminopyrimidines as alk inhibitors | |
| HK40026020B (en) | Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors | |
| HK40026020A (en) | Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors | |
| HK40013399A (en) | 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2024 BY BIRGIT KNAACK Effective date: 20230808 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2025 BY BIRGIT KNAACK Effective date: 20240815 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 AUG 2026 BY BIRGIT KNAACK Effective date: 20250819 |